Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis

Clinical Infectious Diseases

Volumn 36, Issue 5, 2003, Pages 560-566

  Syriopoulou, Vassiliki ^a,b   Daikos, George L ^a   Theodoridou, Maria ^a   Pavlopoulou, Ioanna ^a   Manolaki, Archondia G ^a   Sereti, Evagelia ^a   Karamboula, Aikaterini ^a   Papathanasiou, Dimitra ^a   Krikos, Xenophon ^a   Saroglou, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE;

ABSCESS; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; FEMALE; FEVER; HOSPITAL CHARGE; HUMAN; INJECTION SITE; LABORATORY TEST; MALE; MICROBIOLOGICAL EXAMINATION; MYOCARDITIS; PAPULAR SKIN DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT COURSE THERAPY; SIDE EFFECT; SPLEEN SIZE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHILD, PRESCHOOL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; LIPIDS; MALE; MEDITERRANEAN REGION; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037373019     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367843     Document Type: Article

References (26)

1. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995; 73:191-7.
2. Maltezou HC, Siafas C, Mavrikou M, et al. Visceral leishmaniasis during childhood in southern Greece. Clin Infect Dis 2000; 31:1139-43.
3. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
4. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-9.
5. Davidson RN, Croft SL, Scott AG, Maini M, Moody AH, Bryceson ADM. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991; 337:1061-2.
6. Lira, R, Sundar S, Makharia A, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180:564-7.
7. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42-8.
8. Berman JD. Editorial response: U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:49-51.
9. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 2000; 4:158-77.
10. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001; 45:2185-97.
11. di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131:271-7.
12. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938-43.
13. van Eys GJ, Schoone GJ, Kroon NC, Ebeling SB. Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites. Mol Biochem Parasitol 1992; 51:133-42.
14. New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981; 8:371-81.
15. Croft SLR, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 1991; 28(Suppl B):111-8.
16. di Martino L, Raimondi F, Scotti S, Davidson RN, Gradoni L, Giacchino R. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87:477.
17. Davidson RN, di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87:75-81.
18. Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21:188-93.
19. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex (ABLC). J Infect Dis 1996; 173:762-5.
20. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127:133-7.
21. Freire M, Badaro F, Avelar ME, et al. Efficacy and tolerability of liposomal amphotericin B (AmBisome) in the treatment of visceral leishmaniasis in Brazil. Braz J Infect Dis 1997; 1:230-40.
22. Gangneux JP, Sulahian A, Garin YJF, Farinotti R, Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 1996; 40:1214-8.
23. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997; 41:2089-92.
24. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex treatment. Ann Trop Med Parasitol 1998; 92:755-64.
25. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323:419-22.
26. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.